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Abstract

Background: Despite guidelines that
recommend strongly against Sliding Scale Insulin (SSI) it
continues to be the most commonly insulin regimen used in
hospitals to treat hyperglycemia. In addition to being
reactionary to a glucose that has already increased, SSI offers
practical challenges in the randomness of the doses of insulin
prescribed and often a disconnect with glucose testing that
should be occurring in congruence to the insulin dosing.
While many clinical trials have shown improved glycemic
control in critical care patients receiving intravenous insulin;
few studies have demonstrated the efficacy of subcutaneous
(SQ) insulin in this setting. In this study, we have evaluated
the safety and efficacy of SQ insulin administration utilizing
a computerized program, the Clarian GlucoStabilizer™
Subcutaneous Program (CGS-SQ) in the intensive care unit
(ICU). This program is designed to overcome some of the
most common barriers of SQ insulin delivery, those of dose
calculation and timing.
Methods: A computerized SQ insulin delivery program -The
Clarian
GlucoStabilizer™
Subcutaneous
Program
(CGS-SQ)- was made available to ICU practitioners,
facilitating standardized calculation of insulin doses and
incorporating reminder alarms for blood glucose (BG)
testing. This program used three defaults Insulin Sensitivity
Factors (ISF) and Insulin to Carbohydrate Ratios (CR) to
calculate insulin doses. Additionally, there is an option for
practitioner determined ISF and ICR. Patients, aged ≥ 18
years, initiated on the CGS-SQ and admitted to the (ICU)
were eligible for inclusion in this retrospective evaluation.
Patients were divided into four groups based on initial
insulin sensitivity factor (ISF) and carbohydrate ratio (CR).
Three of the groups used a default ISF and CR; ISF 60, CR
15; ISF 30, CR 10 and ISF 15, CR 8. These groups were

compared with those where the practitioner specified an
individualized ISF and CR, referred to as PDS (practitioner
defined setting). Primary endpoints included: mean glucose,
time to target glucose, hyperglycemic and hypoglycemic
events.
Results: In the 1,384 patients identified, patients initiated
with a predefined setting had lower mean glucose compared
to patients with PDS (ISF 60, CR 15: 135 mg/dL vs. ISF 30,
CR 10: 140 mg/dL vs. ISF 15, CR 8: 134 mg/dL vs. PDS:
143 mg/dL; p < 0.0001). Patients in the default settings had
shorter time to target glucose and decreased incidence of
hyperglycemia and hypoglycemia.
Conclusions: Using a system of computerized prompts with
standardization of insulin dose calculation, SQ insulin can be
effectively used in the treatment of ICU patients to target BG
of 100-150 mg/dL with minimal risk of hypoglycemia.
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1. Introduction
Hyperglycemia in the critical care setting has shown to
contribute to increased morbidity and mortality and canlead
to multiple complications such as increased risk of infection,
increased mechanical ventilation time, changes in
hemodynamics, and changes in renal function [1, 2]. The
American Association of Clinical Endocrinologists and
American Diabetes Association therefore recommend
control of hyperglycemia in critically ill patients with
threshold glucose of ≥180 mg/dL [3]. This consensus
committee statement also recommends frequent glucose
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monitoring to decrease hypoglycemia while achieving
glucose control [3] since hypoglycemia itself can also have
deleterious effects on the patient.
Although many clinical trials have evaluated appropriate
glucose goals in the ICU, controversy remains as to specific
targets that would favor patient outcomes and decrease
mortality in the critical care setting [4-5].Most studies
evaluating the benefit of tight glucose control in the (ICU)
have utilized intravenous (IV) insulin [3, 6-9]. We have
published earlier, the results of our computerized Clarian
GlucoStabilizer™
Intravenous
Program
(CGS-IV)
demonstrating its effectiveness and safety in achieving and
maintaining tight glucose targets in the ICU[10]. However,
subcutaneous (SQ) insulin therapy continues to be used,
primarily as sliding scale insulin (SSI)not only in non-ICU
but also in critical care settings. In order to effectively
control glucose with insulin therapy, three critical attributes
need to be met: standardization of insulin dose calculation,
timely checking of BG, and standardized insulin dose
readjustment. If one or more of these attributes are not met,
the potential for persistent hyperglycemiaor development of
hypoglycemiamay result. Appropriate protocol selection and
implementation therefore is vital to the success of any
glucose management strategy.
Following the demonstrated safety and efficacy of the
CGS-IV program, we sought solutions to the challenges we
were encountering in SQ insulin delivery. Paper Protocols
promoting basal bolus insulin were introduced and were
modestly successful. There continued to be a demand for a
more standardized solution to calculate and administer SQ
insulin within the hospital system. In 2006, Clarian Health,
now Indiana University Health (IUH), launched the Clarian
GlucoStabilizer™ Subcutaneous Program (CGS-SQ), to
meet this need. This is a computerized program developed to
standardize SQ insulin administration and reduce calculation
errors [11].The program can be used to recommend most
aspects of SQ insulin dosing including individual: prandial
insulin doses, correction insulin doses, and treatment for
hypoglycemia. The program is initiated by the practitioner,
and enhances compliance with audible and visual reminder
alarms for glucose testing [11]. Each insulin dose is
administered SQ by the patient’s nurse, in response to
prompts from the program. The CGS-SQ has traditionally
been utilized in non-critically ill patients; however, in recent
years the program has also found acceptance inthe ICU.
The objective of this study was to evaluate the efficacy and
safety of the Clarian SQ GlucoStabilizer on glycemic control
in the ICU.

2. Methods
This study is a retrospective data analysis evaluating the
efficacy and safety of SQ insulin administration utilizing the
CGS-SQ on glycemic control in the ICU. The study included
data collected at two large academic medical centers,
University Hospital (UH) and Methodist Hospital (MH) in
Indianapolis, Indiana from January 1, 2009 to June 30, 2009.

Details of the CGS –SQ has been described elsewhere [11].
Briefly, once the practitioner orders SQ insulin via a
standardized order set, the nurse initiates the computerized
program. The program utilizes insulin sensitivity factors
(ISF), carbohydrate ratios (CR), and blood glucose (BG)
testing every three hours orevery four hours to facilitate
rapid-acting insulin dose calculation and administration. ISF
is the estimated reduction in BG that would occur with one
unit of rapid-acting insulin. CR is the estimated number of
grams of carbohydrate covered by one unit of rapid-acting
insulin. The practitioner can use one of the available default
settings for these parameters (ISF 60, CR 15; ISF 30, CR 10
and ISF 15, CR 8). These default settings are based on body
weight and were decided upon based on a consensus of
physicians, pharmacists and nurses with experience in
inpatient hyperglycemia management. If a patient weighs
less than 68 kg the default setting is an ISF 60, CR 15 and if
68 kg or greater an ISF 30, CR 10 is the default. An ISF 15,
CR 8 setting is also available and can be chosen by the
treating practitioner based on the patient’s perceived insulin
needs. In addition, the treating practitioner has the ability to
customize practitioner defined settings (PDS) for ISF or CR.
The nurse enters the selected parameters into the software
along with the starting BG value and the program clock is
initiated. Glucose is tested every 3 or 4 hours, depending on
the order set used.At MH, the order set utilizes 3 hour
glucose testing while at UH a 4 hour glucose testing
frequency is the default. The timings of 3 or 4 hours for
glucose testing were based on a consensus similar to the ISF
and CR calculations. In addition the program sets a default
BG target range of 100-150 mg /dL and the ISF is designed
to target to the mid-point of this target range. Practitioners
are able to modify the target range to suit their patient’s
particular needs.
When the program alarm (visual and audible) initiates for
glucose testing, the treating nurse uses a point of care device
to obtain a glucose reading, which is entered into the
computer program. The program then determines the amount
of insulin to be administered based on the patient’s glucose
reading, target glucose range, ISF, and CR. For prandial
insulin dosing, the program calculates a dose of rapid-acting
insulin utilizing the total number of grams of carbohydrate
consumed in the meal or bolus tube feeding. For correction
insulin dosing, the program calculates a dose of rapid-acting
insulin based on the current BG and the midpoint of the
target range using the ISF. Hypoglycemia recovery
instructions include a standardized dose of dextrose 50% or
grams of oral carbohydrates to be administered followed by
BG testing every 15 minutes until the BG is ≥70 mg/dL.
Numerous safeguards are built into the software such as
alerts for potentially unsafe insulin doses and criteria for
calling the practitioner [11].Guidelines for basal insulin
administration are not part of the current version of the
software; this insulin is administered separately based on
practitioner instructions.
In this study, comparison of initial ISF, CR, and frequency
of glucose testing were evaluated to determine the most

Advances in Diabetes and Metabolism 1(1): 29-35, 2013

appropriate initial program settings. Patients were identified
through the CGS-SQ database along with the hospital patient
database. All adult patients, 18 years of age or older,
admitted to an ICU and initiated on the CGS-SQ program
were screened but data was only analyzed for those patients
in whom the practitioner had selected a target BG range of
100-150 mg/dL which was standard of care at MH and UH
during the study period. Patients were excluded if they
received IV insulin while in the ICU. This study included a
mixed ICU population including: medical, surgical,
cardiovascular, trauma, neurosurgical, pulmonary, bone
marrow transplant, and solid organ transplant patients.
Patients were categorized into one of four groups based on
initial ISF and CR settings. Patients either had one of three
predefined ISF and CR settings (ISF 60, CR 15; ISF 30, CR
10; ISF 15, CR 8) or PDS for ISF and CR.
The primary endpoints included: time to target glucose
range, time in target glucose range, mean ICU glucose,
hyperglycemic events, hypoglycemic events, and frequency
of glucose testing. To evaluate hyperglycemic events, blood
glucose values were studied in intervals of 10 mg/dL starting
at ≥ 150 mg/dL to ≥ 250 mg/dL. Hypoglycemic events were
also studied at decrements of 10 mg/dL starting at ≤ 70
mg/dL to ≤ 40 mg/dL.
2.1. Statistical Analysis
Time in target glucose range and mean glucose were
compared between the four treatment groups using
ANOVA while hyperglycemic and hypoglycemic events
were analyzed using Chi-Square analysis. The time to
achieving target glucose range in each group was compared
using Mantel-Cox analysis. A p-value of < 0.05 was
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established as statistically significant.

3. Results
During the 6 month study period, 1,384 patients met the
inclusion criteria. A total of 34,514 blood glucose
measurements were recorded. Seven hundred seventy-one
patients (56%) had initial blood glucose readings outside
their target glucose range (100-150 mg/dl); in the remainder,
the program was initiated by the practitioner presumably to
keep BG in target of 100-150 mg/dl during the ICU stay.
For those patients with initial BG outside the target range at
program initiation, the mean admission glucose was 174.1 ±
62.2 mg/dL and the mean time to achieving the target of
100-150 mg/dl was 18.5 ± 1.37 hours (median 9.23 ± 0.43
hours). The mean glucose after achieving target was 137 ±
28.7 mg/dL. For those in the target range on admission, the
mean admission glucose was 126.1 ± 14.0 mg/dL and the
mean glucose while in the ICU was 131.8 ± 26.1 mg/dL.
Patients initiated with one of the predefined settings had a
shorter time to achieving the target glucose range compared
to practitioner defined settings (Table 1). Patients in the ISF
15, CR 8 group had the shortest mean time to target range of
11.2 hours (median 6.9 hours). Overall, 81 patients (10.5%)
did notachieve the target range of 100-150 mg/dl during their
treatment in the ICU with the CGS-SQ.
Patients initiated with one of the predefined settings spent
more time within the target glucose range (ISF 60, CR 15:
52% vs. ISF 30, CR 10: 46% vs. ISF 15, CR 8: 54 % vs. PDS:
40%; p < 0.0001 Table 1). In addition, mean glucose within
the default groups was lower than the PDS group (ISF 60,
CR 15: 135 mg/dL vs. ISF 30, CR 10: 140 mg/dL vs. ISF 15,
CR 8: 134 mg/dL vs. PDS: 143 mg/dL; p < 0.01).

Table 1. Target Glucose Attainment

Patients initially
out of range who
reached target
Median time to
target range
100-150 mg/dL
(hrs)

ISF 60, CR 15
(n=106)

ISF 30, CR10
(n=374)

ISF 15, CR 8
(n=193)

PDS
(n=98)

98 (92%)

322 (86%)

182 (94%)

88 (90%)

*

11.1

10.1

6.9

14.5

*

52%

46%

54%

40%

Time in range

p-value
p<0.001

p<0.001

†

p<0.01

*

Comparison between all groups
Each group compared to PDS

†

The frequency of hyperglycemia was evaluated in all patients, including those initially within the target BG range and
those initially outside of the target BG range. Evaluation started at measurements of blood glucose ≥ 150 mg/dL and then in
10 mg/dL increments up to ≥ 250 mg/dL. The overall frequency of hyperglycemia (BG ≥150 mg/dL) was 24.5% (n=8,442
BG measurements). Patients initiated with one of the default settings had fewer hyperglycemic events compared to
practitioner initiated settings (Table 2). The ISF 15, CR 8 group had the fewest hyperglycemic events with 21.4% of
measurements being ≥ 150 mg/dL and 0.8% being ≥ 250 mg/dL.
The frequency of hypoglycemia was also evaluated in all patients. Measurements were evaluated starting at a blood
glucose of ≤ 70 mg/dL and then in 10 mg/dL decrements down to severe hypoglycemia of ≤ 40 mg/dL. The overall incidence
of hypoglycemia (BG ≤ 70 mg/dL) was low at 1.1% (n=368/34,514 BG measurements). Patients initiated with one of the
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default settings had a lower incidence of hypoglycemia compared to PDS settings (Table 2). The incidence of severe
hypoglycemia (BG ≤ 40 mg/dL) was extremely low (0.1% of all readings) (Table 2). On a per patient basis, patients with PDS
experienced more hypoglycemia 0.38 events/patient (Table 3).
Table 2. Blood Glucose Measurements

Hypoglycemia
Measurements
≤ 70 mg/dL
Measurements
≤ 60 mg/dL
Measurements
≤ 50 mg/dL
Measurements
≤ 40 mg/dL
Hyperglycemia
Measurements ≥
150 mg/dL
Measurements ≥
160 mg/dL
Measurements ≥
170 mg/dL
Measurements ≥
180 mg/dL
Measurements ≥
190 mg/dL
Measurements ≥
200 mg/dL
Measurements ≥
210 mg/dL
Measurements ≥
220 mg/dL
Measurements ≥
230 mg/dL
Measurements ≥
240 mg/dL
Measurements ≥
250 mg/dL

ISF 60, CR 15
(n=191)

ISF 30, CR 10
(n=656)

ISF 15, CR 8
(n=374)

PDS
(n=163)

0.9%

0.9%

1.2%

1.3%

NS

0.3%

0.3%

0.5%

0.6%

NS

0.1%

0.1%

0.2%

0.1%

NS

0%

0%

0.1%

0%

NS

22.7%

26.5%

21.4%

29.7%

p<0.01

17.4%

20.2%

15.2%

23.1%

p<0.01

13.4%

15.2%

10.7%

18.6%

p<0.01

9.6%

11.5%

7.4%

14.3%

p<0.01

7.3%

8.9%

5.1%

11.4%

p<0.01

5.6%

6.9%

3.6%

9.3%

p<0.01

4.2%

5.2%

2.6%

7.3%

p<0.01

3.2%

4.1%

2.0%

6.2%

p<0.01

2.4%

3.1%

1.5%

4.8%

p<0.01

1.8%

2.5%

1.1%

3.9%

p<0.01

1.4%

2.0%

0.8%

3.1%

p<0.01

*

p-value

*

Each default setting compared to the PDS group
NS = not significant

Table 3. Hypoglycemic Events

Patients with
hypoglycemia
(BG ≤ 70 mg/dL)
Mean episodes of
hypoglycemia per
patient
Total number of
hypoglycemic events
(BG ≤ 70 mg/dL)
*

ISF 60, CR 15
(n=191)

ISF 30, CR 10
(n=656)

ISF 15, CR 8
(n=374)

PDS
(n=163)

11%

9%

15%

19%

*

0.21

0.20

0.36

0.38

†

40

131

135

62

ISF 30, CR 10 compared to PDS. No difference found between other groups.
ISF 60, CR 15 and ISF 30, CR 10 compared to PDS. No difference found between other groups.

†

p-value
p<0.01
p<0.01
--

Advances in Diabetes and Metabolism 1(1): 29-35, 2013

33

The relationship of frequency of glucose testing to the efficacy and safety of the program was also evaluated. Patients who
had every 3 hour glucose testing, irrespective of ISF or CR settings, had a shorter time to target glucose range, more time
spent within the target glucose range, lower mean glucose, and decreased frequency of hyperglycemia (Table 4).
Table 4. Frequency of Glucose Testing

Time to target range (hrs)
% of time in target range
Mean glucose (mg/dL)
Measurements ≥ 150 mg/dL
Measurements ≤ 70 mg/dL

Every 3 hours
10.5
57%
132 ± 34
19.5%
1.1%

Every 4 hours
17.4
52%
137 ± 39
24.6%
1%

PDS
22.2
32%
149 ± 52
32.9%
1.4%

*

p-value
p<0.01
p<0.01
p<0.01
p<0.01
NS

*

Comparison between every 3 hours and every 4 hours compared to PDS
NS = not significant

4. Discussion
Subcutaneous insulin delivery in the hospital has its
challenges but is still the preferred route of insulin delivery.
The first challenge is effectively getting patients within a
preset glucose target. Our data shows that with the Clarian
SQ GlucoStabilizer (CGS-SQ) mean time to target of
100-150 mg/dl was 18.5 hours (median 9.2 hours),
percentage of hyperglycemic BG readings (≥ 150 mg/dL)
24.5%, and mean BG after target achieved 137 ± 28 mg/dL.
When we compare this to our efficacy outcomes of the
Clarian IV GlucoStabilizer, the mean time to target of
80-110 mg/dLwas 6.9 hours (median 6 hours); percentage of
hyperglycemic BG readings (≥150 mg/dL) 8.0 %; and mean
BG after target achieved 98.1 mg/dL [10].
When
comparing the two programs, it is important to note
differences in goal blood glucose ranges and insulin
administration. However, if we look individually at each
ISF and CR setting, it differs; for example, the mean for ISF
15, CR 8 mean time to target was only 11 hours. These data
suggest that both the IV and SQ CGS programs are
efficacious in correcting BG in critically ill patients.
Regarding safety, the CGS-IV resulted in 3.5% of the BG
readings ≤ 70 mg/dL, while only 0.4% were ≤ 50 mg/dL. The
hypoglycemic events for the CGS-SQ were 1% ≤ 70 mg/dL,
0.4% ≤ 60 mg/dl, 0.1% ≤ 50mg/dL and only 0.04% ≤ 40
mg/dL. These data suggest that although there is a greater
risk of hypoglycemia with IV insulin, the risk of severe, life
threatening hypoglycemia is not different in the ICU when
computerized IV or SQ insulin dosing tools are used.
The target BG used in our institution with the CGS-SQ
was far more stringent than those recommended by the
AACE/ADA consensus panel [3], in whose opinion a BG
range of 140-180 mg/dL is more acceptable for most
institutions.Amongst the concerns that led the consensus
panel [3] to raise their recommended targets from the earlier
80-110 mg/dL were the potential for increase in mortality
thought to be contributed, at least in part, by the risk of
hypoglycemia when trying to achieve tight glucose control.
Our data earlier with the CGS-IV [10], and now with the
CGS-SQ, however clearly demonstrates that tighter glucose
control can be achieved with minimal risk of hypoglycemia
in the critically ill patient, if one uses computer driven

insulin administration algorithms.
Our study does have limitations. It is a retrospective
evaluation of data, and not a randomized controlled trial.
However, this is an analysis of data from a real world ICU
setting where treating practitioners were making the clinical
decision to use SQ insulin for their patients. The CGS-SQ is
a computerized tool that offered them a means to standardize
dose calculations and, after initiation, ensure compliance in
insulin delivery and glucose testing. In addition to
standardization, the computerized program offers additional
advantages over a paper based SSI insulin regimen, assisting
in nursing reminders and hypoglycemia protocols. As
such,this meaningful analysis is able to demonstrate that
when treating practitioners use a computer program, safe and
effective SQ insulin delivery is possible even in the ICU.
Another potential limitation is documentation of basal
insulin administration. Because of the limitations within our
data collection software, we were not able to determine
which of the patients included in our study received basal
insulin. Anecdotally, however, we know that the vast
majority of the patients in our institution are treated with
both basal and bolus insulin regimens.Lastly, although the
study was conducted in two different hospitals, both
hospitals belong to the same health care system with a
sharing of resources and staff. There is long standing
glycemic control initiative in these institutions; the
Systematic Utilization of Glucose Assessment and Response
(SUGAR™) Program [11-13] with heightened awareness
towards insulin treatment and aggressive monitoring of BG
which could have influenced the results. However, part of
the reason for the heightened awareness is the CGS programs
themselves and their associated alarm functions which
facilitate better care. Having the study repeated therefore in
other institutions where such a heightened awareness does
not exist may be of benefit.
Irrespective of targets for glucose control, insulin is the
only safe and recommended means of managing hospital
hyperglycemia [3]. This drug however continues to remain a
high-alert medication and therefore standardization of
insulin delivery is of paramount importance [14]. Our data
show the reminder systems and standardized dosage
calculations, integral to the software of the CGS-SQ, provide
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a safe and effective means for reducing insulin
administration errors. Given that over 35% of the patients
being admitted to the hospital manifest hyperglycemia [15] it
is imperative that we have safe and effective insulin delivery
systems for the practitioners to use. The CGS-SQ has been
shown to be safe and effective now, not only in the
non-critically ill [11] but also in the treatment of the ICU
patient.

5. Conclusion
The mainstay treatment of hyperglycemia in the ICU has
always been IV insulin which is a very labor intensive
process. The Clarian GlucoStabilizer (CGS-SQ) is the first
software program that has evaluated the effectiveness of SQ
insulin in the treatment of the critically ill patient. Our study
has shown that by using a system of computerized prompts
with standardization of insulin dose calculation and reminder
alarms, SQ insulin can be effectively used in the treatment of
ICU patients to target BG of 100-150 mg/dL with minimal
risk of hypoglycemia.
This study offers a critical insight into the safety and
effectiveness of SQ insulin use in the ICU. Data from this
analysis demonstrates the CGS-SQ can be used to design
future randomized clinical trials, where the variability
created by different insulin protocols can be minimized
allowing for a true testing of the hypothesis of the
effectiveness of tight glucose control and its effects on
outcomes of morbidity and mortality in the critically ill
patient.
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Glossary
BG= Blood Glucose, CGS-SQ=Clarian GlucoStabilizer™
Subcutaneous Program, CR = Insulin to Carbohydrate Ratio,
ISF = Insulin Sensitivity Factor, PDS = Practitioner Defined
Settings, SSI = Sliding Scale Insulin, SQ= Subcutaneous
Insulin
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